EP0964672A1 - Zusammensetzung zur verbesserung der haut oder des haares - Google Patents

Zusammensetzung zur verbesserung der haut oder des haares

Info

Publication number
EP0964672A1
EP0964672A1 EP97903746A EP97903746A EP0964672A1 EP 0964672 A1 EP0964672 A1 EP 0964672A1 EP 97903746 A EP97903746 A EP 97903746A EP 97903746 A EP97903746 A EP 97903746A EP 0964672 A1 EP0964672 A1 EP 0964672A1
Authority
EP
European Patent Office
Prior art keywords
skin
composition
composition according
enhancer
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97903746A
Other languages
English (en)
French (fr)
Other versions
EP0964672A4 (de
Inventor
Dean Hsieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conrex Pharmaceutical Corp
Original Assignee
Hsieh Phyllis (executrix for deceased inventor)
Conrex Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsieh Phyllis (executrix for deceased inventor), Conrex Pharmaceutical Corp filed Critical Hsieh Phyllis (executrix for deceased inventor)
Publication of EP0964672A1 publication Critical patent/EP0964672A1/de
Publication of EP0964672A4 publication Critical patent/EP0964672A4/de
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair

Definitions

  • This invention relates to means for improving a physiologic condition of the body. More particularly, this invention relates to a composition which is effective in enhancing the qualities of skin or hair.
  • the present invention relates to the provision of an improved composition for enhancing the qualities of skin or hair.
  • composition which is effective in enhancing the qualities of skin or hair and which comprises: (A) a skin- treating or hair-treating compound; (B) an enhancer, as described below; (C) a carrier; and optionally (D) a cosmetic additive.
  • Another aspect of the present invention is the provision of a method for enhancing one or more properties of the skin or hair comprising applying to the skin or hair a composition of the present invention.
  • the composition is applied to the bodily part in the form of a cream or lotion.
  • the composition of the present invention comprises a skin- or hair-treating compound, an enhancer, a carrier, and optionally a cosmetic additive.
  • skin-treating compound means a material which is effective in enhancing one or more properties of skin as evidenced by statistically significant differences between the quality of untreated skin and skin treated with said material, at the 95% level of confidence, using standard methods of evaluation which are known to persons skilled in the art.
  • Examples of skin characteristics or properties that are capable of being improved by a skin-treating compound include: (A) smoothness of the skin; (B) thickness of the epidermal layer of the skin; (C) increase in the cellular density of the skin; (D) reduction in the depth of interossei; (E) elasticity of the skin; and (F) texture of the skin.
  • Methods for evaluating in an objective way skin properties of the aforementioned type are well known to persons skilled in the art. They include, for example, the use of clinical assessments, photographic assessments, silastic castings, ultra-sound evaluation, histological examination, punch biopsies, and tape stripping.
  • Examples of classes of materials for use as skin- treating compounds in the practice of the present invention include nutrients, modifiers, rejuvinators, hormones, regulators, immunomodulators, moisturizers, and stimulators.
  • Examples of skin-treating materials for use in the practice of the present invention include: nutrients - vitamins, amino acids, and carbohydrates; modifiers - melanin and antioxidants; rejuvinators - growth factors and human growth hormones; hormones - estrogens, progesterones and other steroids, and growth hormones; regulators - peptides, proteins, and anti-sense variations; immunomodulators - beta 1, 3-glucan and farnesol; moisturizers - vegetable oils, beeswax, and other waxes, lanolins, fatty acid esters, mineral oils, and other hydrophobic materials; and stimulators - tocopheryl nicotinate, retinoids, and alpha- hydroxy acids.
  • a plurality of skin-treating compounds can be used in the composition.
  • the minimum percent improvement which is imparted by the skin-treating compound (s) to the skin and which constitutes a statistically significant difference will vary depending on the skin property being evaluated, as well as on sample size and distribution. For example, in evaluating epidermal thickness, an improvement of 10 % or greater is considered by persons skilled in the art as a statistically significant difference. On the other hand, in evaluating elasticity of skin, an improvement of at least about 30 % would be considered by persons skilled in the art as constituting a statistically significant difference.
  • the skin-treating compound (s) is used in conjunction with an enhancer which is a compound within the scope of Formula I below.
  • A is a group having the structure
  • X and Y are defined; m and n are integers having a value of from 1 to 20 and the sum of + n is not greater than 25; p is an integer having a value of 0 or 1; q is an integer having a value of 0 or 1; r is an integer having a value of 0 or 1; and R is hydrogen or an alkyl group having from 1 to 6 carbon atoms and may be straight chained or branched; with the proviso that when p, q and r have a value of 0 and Y is oxygen, m + n is at least 11.
  • R is alkyl
  • it can be, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec - butyl, amyl, hexyl, and the like.
  • a plurality of enhancers can be used.
  • the enchancers for use in the practice of this invention are non-toxic and are compatible with skin/hair treating compounds which comprise the composition of this invention. Additional improvements in the qualities of the skin are achieved by the use of the enhancer (s) in combination with the skin-treating compound. Such improvements are identified and evaluated by use of the same type of methodologies referred to hereinabove in connection with the skin-treating compound (s) .
  • the enhancer is a cyclic lactone compound wherein both X and Y are oxygen, q is 1 and r is 0, a cyclic diester (compounds wherein both X and Y are oxygen and both q and r are 1) , and a cyclic ketone (compounds wherein both q and r are 0 and Y is oxygen) .
  • m+n is preferably at least 3.
  • m+n is preferably from 11 to 15 and p is preferably 0.
  • Particularly preferred enhancers for use of the practice of the present invention include macrocylcic ketones and lactones of Formula I above.
  • a highly preferred enhancer is cyclopentadecanolide.
  • the skin-treating compound or a mixture of skin-treating compounds should be used in an amount which is effective in improving the quality of the skin.
  • the minimum amount (s) needed to achieve the improvement will vary depending on the particular skin-treating compound or mixture of skin-treating compounds that are used. Generally speaking, it is believed that the skin-treating compound (s) will comprise at least about 0.01 wt.% of the composition. Typically, the skin- treating compound(s) will comprise about 0.1 to about 10 wt.% of the composition. Preferably, the skin-treating compound (s) will comprise about 0.5 to about 3 wt.% of the composition.
  • the enhancer or a mixture of enhancers can be used in an amount at least effective to impart additional improvements to the skin, that is, improvements beyond those provided by the skin-treating compound. It is believed that, for most applications, the enhancer will comprise about 0.1 to about 30 wt.% of the composition, with a preferred range of enhancer being about 0.5 to about 10 wt.%, and a particularly preferred range comprising about 2 to about 5 wt.% of the composition.
  • the skin-improving composition of the present invention will generally include also a carrier in which the other ingredients comprising the composition are either dissolved or dispersed in the form of solid particles or liquid droplets.
  • a carrier in which the other ingredients comprising the composition are either dissolved or dispersed in the form of solid particles or liquid droplets.
  • Any suitable material can be used as the carrier, for example, materials which are suitable for use in pharmaceutical and cosmetic compositions.
  • carriers include water, alcohol, glycerine, sorbitol, propylene glycol, vegetable- and animal-derived oils, waxes, acids, alcohols, esters, ethers, amides, ethoxylates and propoxylates, ethylene and propylene glycol ethers, mineral oils and waxes, silicone oils and waxes, and surfactants.
  • the carrier can comprise one or more compounds.
  • the carrier will comprise about 10 to about 95 wt.% of the composition.
  • the composition will include also one or more compounds which impart other desired properties to the composition.
  • Such compounds will typically comprise materials of the type that are used as additives in cosmetic compositions. Examples of such materials are fragrances, colorants, including pigments or dyes, preservatives, thickening agents, pH controlling agents, stabilizers, surfactants, and emulsifiers.
  • the form of the composition can be liquid, semi-solid, or solid.
  • the composition can be formulated so that it can be dispersed from an aerosol container. For convenience and ease of application, the use of the composition in a cream or lotion form is recommended.
  • the skin-improving composition can be applied to the skin as often as needed to achieve the desired improvements.
  • the frequency of application will vary depending on the nature of the composition and the involved skin condition. In general, the application of the composition twice a day (for example, in the morning and the evening) will be suitable for treating many conditions and can be continued for as long as is required to obtain the desired results, for example, weeks or months or indefinitely. For some conditions, the composition can be applied every two or three days. In treating the skin of the hands, consideration should be given to applying the composition after every washing.
  • Compositions for treating hair are also within the scope of the present invention.
  • Such compositions can comprise hair-treating compounds, for example, materials which function as hair conditioners and compounds which improve the manageability of hair.
  • Such compositions can comprise a hair-treating compound and the enhancer of Formula I above, as well as other ingredients, and in amounts as described above in connection with the skin-improving composition.
  • the enhancer of the present invention can be used to advantage in any type of skin-enhancing composition which includes one or more skin- treating compounds that do not readily or easily penetrate the skin epithelial barrier.
  • Such compositions are well known to those skilled in the art.
  • An exemplary class of such compositions is an anti-oxidant composition.
  • Such compositions typically comprise a variety of natural nutrients, including, for example, vitamins, which function to rejuvenate the skin, retard the signs of aging of the skin and maintain the vitality of skin cells.
  • Retin A a material whose anti-wrinkle property has been well documented, it was determined that the performance of the composition of the present invention was equal to that of Retin A in terms of effecting an increase in epithelial thickness, but without the side effects experienced with Retin A.
  • Examples 1 to 3 below are illustrative of anti-oxidant compositions which promote the natural repair process and retard aging of the skin by providing skin cells with beneficial natural nutrients.
  • the enhancer used in the compositions is cyclopentadecanolide. It is believed that the enhancer functions to aid in the delivery of the nutrients effectively to the skin cells for their nourishment. This results in rejuvenation of the skin, imparting to the skin a radiant and youthful appearance.
  • the principal variations among the compositions are related to differences in viscosity and concentrations of ingredients.
  • compositions can be tailor-made for ease and effectiveness of application - for example, for repetitive use during the day, especially after each time the body or parts of the body, such as the hands, are washed or otherwise cleaned, or for application at night prior to sleep.
  • Carbomer 934 0.10 Poly (Vinylpyrrolidone) /1-Eicosene Copolymer 1.00 Methylparaben 0.20
  • Vitamin E Acetate 1.50 Alpha-Bisabolol 1.00
  • Panthenol (Pantothenyl Alcohol) 1.00
  • Panthenol (Pantothenyl Alcohol) 1.000
  • compositions of Examples 1 to 3 are formulated into a substantially homogeneous composition with standard mixing, stirring, or shearing equipment, including high shear, as well as motionless or other mixers, for example, at room temperature - 90°C, to form a creamy emulsion or lotion with a smooth feeling.
  • the resultant compositions can be packaged, as appropriate, in plastic or aluminum tubes, glass or plastic jars, or glass or plastic bottles.
  • the compositions evidence gross physical stability even under drastic conditions, for example, at 60°C for 3 months.
  • Example 2 The hand and body cream of Example 2 is evaluated for effectiveness in tests involving humans (15 Caucasians, aged 50 years and older) .
  • the test subjects use the composition of Example 2 or a placebo cream, according to the blind code, for the first 2 months and then all subjects use the composition of Example 2.
  • the test compositions are rubbed into the hands daily at night before the test subjects retire.
  • the following techniques are used to evaluate the performance of the composition on the back of the hand: (A) photographs; (B) silastic castings; (C) ultrasound B-mode scans; (D) biopsies for histological examination; and (E) ballistometry.
  • the overall effects observed as a result of the use in the evaluations of the composition of Example 2 are summarized hereafter.
  • composition of Example 2 On the basis of photographic assessments (A) above, a comparison of the subjects shows a gradual improvement in the appearance of the dorsal surface of the hands as a result of the use of the composition of Example 2. Study of the photographs reveal that there is a decrease in the number of lines, a decrease in the depth of the interossei, and a general improvement in the smoothness of the skin. Use of composition of Example 2 appears to improve both the quality of the stratum corneum and the hydration of the epidermis and dermis. Improvement in the interossei depth, as manifested by a decrease in the depth, would indicate a dermal improvement .
  • Silastic castings of (B) above are evaluated and compared by two independent scorers. Changes in the skin's topography are rated according to the following scale: positive response; no response or no change; and negative response or worsening. These results are then averaged. At 30 days, there is no significant difference in the skin's topography. At 90 days, the silastic castings show that 60% of the subjects exhibited a positive response in the skin's topography, and at 180 days, 73% of the subjects have a positive response.
  • epidermal thickness increases by 19% over the course of the study, with a 50% increase being found in epidermal thickness in some subjects.
  • Granular layer increases in all subjects to at least double in thickness. This increase is estimated by the number of granular cells.
  • Stratum corneum appearance is markedly different in most subjects. From a compacted initial appearance, the stratum corneum assumes a basket weave pattern that is associated with a younger epidermis. Dermal evaluation is difficult to assess in that no special stains are used. Overall most subjects will show an increase in cellularity of the dermis. This finding would be consistent with a restructuring process of the dermis.
  • sunscreen compositions typically contain a plurality of sunscreen agents which are compounds that function to protect the skin by virtue of their ability to absorb various wavelengths of potentially harmful ultraviolet radiation.
  • Sunscreen compositions should have a combination of properties including, for example: (A) the fundamental ability to absorb the involved radiation; (B) the ability to continue to absorb the radiation over a prolonged period of time; and (C) the ability to resist removal upon exposure to water and/or perspiration. It is known that various sunscreen agents penetrate the skin relatively rapidly, with subsequent loss to lower skin layers (dermis) and eventually to systemic circulation.
  • the sunscreen agent (s) in the composition of the present invention is retained at higher concentrations for longer periods of time in the epidermis. It is believed that concentrating the sunscreen agent in the epidermis helps to provide a natural resistance to removal by exposure to physical contact and to water, including perspiration. The extent of this "retaining" effectiveness is dependent on the particular sunscreen agent (s) and carrier used and the concentration of the enhancer.
  • the enhancer used in each of the compositions of Examples 4 and 5 is cyclopentadecanolide.
  • Benzophenone-3 (Oxybenzone) 3.00% w/w
  • the present invention provides an effective means for improving the delivery to the body of a variety of types of materials which have beneficial effects on the body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
EP97903746A 1997-01-09 1997-01-09 Zusammensetzung zur verbesserung der haut oder des haares Ceased EP0964672A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/000154 WO1998030198A1 (en) 1997-01-09 1997-01-09 Composition for enhancing skin or hair

Publications (2)

Publication Number Publication Date
EP0964672A1 true EP0964672A1 (de) 1999-12-22
EP0964672A4 EP0964672A4 (de) 2001-03-21

Family

ID=22260188

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97903746A Ceased EP0964672A4 (de) 1997-01-09 1997-01-09 Zusammensetzung zur verbesserung der haut oder des haares

Country Status (7)

Country Link
EP (1) EP0964672A4 (de)
JP (1) JP2002514203A (de)
KR (1) KR100521787B1 (de)
AU (1) AU731269B2 (de)
CA (1) CA2275971C (de)
IL (1) IL130663A (de)
WO (1) WO1998030198A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826499A1 (de) * 1998-06-13 1999-12-16 Beiersdorf Ag Gegen Bakterien, Mycota, Viren, Parasiten und Protozoen wirksame Substanzen
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20050112084A1 (en) * 2003-11-21 2005-05-26 The Gillette Company Topical cosmetic composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
EP0273202A2 (de) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Verwendung von Hydroxycarbonsäuren zur Verstärkung der therapeutischen Effekte von topischen Zubereitungen gegen Pilzinfektionen und Pigmentflecken
JPH05310543A (ja) * 1992-05-08 1993-11-22 Kao Corp 染毛剤組成物
WO1996012467A1 (en) * 1994-10-20 1996-05-02 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5540853A (en) * 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
EP0855180A1 (de) * 1996-06-11 1998-07-29 Soda Aromatic Company, Limited Antibakterielle stoffe sowie diese enthaltende kosmetika und kleidungsstücke

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121364A1 (de) * 1991-06-28 1993-01-07 Haarmann & Reimer Gmbh Ether von 1-hydroxy-hex-5-en-2-on, verfahren zu ihrer herstellung und ihre verwendung als riechstoffe
JPH08259444A (ja) * 1995-03-24 1996-10-08 Earth Chem Corp Ltd 殺菌効力増強剤及びそれを配合した口腔用組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003473A1 (en) * 1985-12-04 1987-06-18 Dean Hsieh Transdermal delivery of drugs
EP0273202A2 (de) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Verwendung von Hydroxycarbonsäuren zur Verstärkung der therapeutischen Effekte von topischen Zubereitungen gegen Pilzinfektionen und Pigmentflecken
JPH05310543A (ja) * 1992-05-08 1993-11-22 Kao Corp 染毛剤組成物
WO1996012467A1 (en) * 1994-10-20 1996-05-02 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5540853A (en) * 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
EP0855180A1 (de) * 1996-06-11 1998-07-29 Soda Aromatic Company, Limited Antibakterielle stoffe sowie diese enthaltende kosmetika und kleidungsstücke

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199650 Derwent Publications Ltd., London, GB; Class B05, AN 1996-502627 XP002157469 & JP 08 259444 A (EARTH SEIYAKU KK), 8 October 1996 (1996-10-08) *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 118 (C-1172), 25 February 1994 (1994-02-25) & JP 05 310543 A (KAO CORP), 22 November 1993 (1993-11-22) *
See also references of WO9830198A1 *

Also Published As

Publication number Publication date
AU1823897A (en) 1998-08-03
IL130663A0 (en) 2000-06-01
EP0964672A4 (de) 2001-03-21
KR20000069832A (ko) 2000-11-25
JP2002514203A (ja) 2002-05-14
CA2275971C (en) 2008-04-29
IL130663A (en) 2005-12-18
WO1998030198A1 (en) 1998-07-16
KR100521787B1 (ko) 2005-10-14
CA2275971A1 (en) 1998-07-16
AU731269B2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
DE69210515T2 (de) Kosmetisches Mittel
JP3112436B2 (ja) 特に、皮膚の顔貌の明るさを改良し、皺を処置するための角質溶解剤としての蜂蜜の使用
EP0839520B1 (de) Zusammensetzung zur Pflege der Haut, die abgespuelt werden kann
KR20180081814A (ko) 적어도 2종의 (폴리)글리세롤의 지방산 에스테르를 포함하는 조성물, 및 이의 화장품에서의 용도
EP1216696B1 (de) Methode, um das Erscheinen von dunklen Ringen unter den Augen zu vermindern
KR20000047999A (ko) 지방산 또는 지방알콜, 카르복실산 및 글리세롤의 혼합에스테르를 기재로 한 나노에멀젼, 및 화장품, 피부과학및/또는 안과학 분야에서의 그의 용도
KR20070100226A (ko) 색소 침착 예방 또는 개선용 조성물
JPS6251608A (ja) 改良されたモイスチユアライジングロ−シヨン
JP2008231010A (ja) 皮膚外用剤
CN111529438A (zh) 一种虾青素抗氧化精华液及其制备方法
JPH08283139A (ja) 皮膚外用剤
JP2004091376A (ja) 表皮角化正常化剤及びこれを含有する皮膚外用剤
CA2365660A1 (en) Treatment for skin
DE69417424T2 (de) Reinigungsmittel die einem alkanoat als conditioner enthalten
DE69600119T2 (de) Verwendung von Cysteinsäure oder Homocystein zur Förderung der schuppende Haut oder Stimulierung der Epidermiserneuerung
CA2275971C (en) Composition for enhancing skin or hair
EP0679388B1 (de) Kosmetische und/oder dermatologische Zusammensetzung, insbesondere zur Depigmentierung der Haut, und ihre Verwendungen
TW202308591A (zh) 化妝料
CN111840157A (zh) 一种山茶花复方组合物
JP2001131031A (ja) 頭皮頭髪用組成物
JP3556479B2 (ja) 皮膚プレトリートメント剤
CN110464666A (zh) 眼唇霜及其制备方法
MXPA99006422A (en) Composition for enhancing skin or hair
CN114533584B (zh) 一种胶原蛋白酶抗皱面霜
JP2006124399A (ja) 皮膚又は毛髪の増進用組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK ES FR GB GR IE IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CONREX PHARMACEUTICAL CORPORATION

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 7/42 A, 7A 61K 7/44 B, 7A 61K 31/38 B, 7A 61K 31/335 B, 7A 61K 7/48 B, 7A 61K 7/06 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010131

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK ES FR GB GR IE IT LI NL SE

17Q First examination report despatched

Effective date: 20020326

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HSIEH, DEAN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1025735

Country of ref document: HK